Piper Sandler Assumes Otonomy (OTIC) at Overweight, PT Raised to $6

April 13, 2021 8:42 AM EDT
Get Alerts OTIC Hot Sheet
Price: $1.76 -5.38%

Rating Summary:
    8 Buy, 0 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 5 | New: 36
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Piper Sandler analyst Christopher Raymond assumes coverage on Otonomy (NASDAQ: OTIC) with an Overweight rating while raising the price target to $6.00 (from $5.00).

The analyst commented, "While the P3 failure of Otividex this past February represented a setback for the company, we would argue that at current levels the stock reflects little if any value for a full pipeline of targeted agents for the ear, two of which (OTO-313 and OTO-413) have already demonstrated POC efficacy with additional validating readouts expected mid-2022. With shares trading at a discount to peers (OTIC’s EV is <$50M vs a peer group closer to ~$170M), we think the setup is favorable for OTIC shares. Now modeling only OTO-313 and OTO-413, we derive a SoP valuation of $6/sh, representing compelling upside."

For an analyst ratings summary and ratings history on Otonomy click here. For more ratings news on Otonomy click here.

Shares of Otonomy closed at $2.29 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, New Coverage